全文获取类型
收费全文 | 6033篇 |
免费 | 351篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 196篇 |
妇产科学 | 140篇 |
基础医学 | 617篇 |
口腔科学 | 77篇 |
临床医学 | 501篇 |
内科学 | 1418篇 |
皮肤病学 | 72篇 |
神经病学 | 463篇 |
特种医学 | 231篇 |
外科学 | 1041篇 |
综合类 | 206篇 |
一般理论 | 5篇 |
预防医学 | 311篇 |
眼科学 | 137篇 |
药学 | 531篇 |
中国医学 | 39篇 |
肿瘤学 | 361篇 |
出版年
2023年 | 38篇 |
2022年 | 101篇 |
2021年 | 229篇 |
2020年 | 125篇 |
2019年 | 199篇 |
2018年 | 223篇 |
2017年 | 162篇 |
2016年 | 158篇 |
2015年 | 186篇 |
2014年 | 275篇 |
2013年 | 345篇 |
2012年 | 473篇 |
2011年 | 486篇 |
2010年 | 274篇 |
2009年 | 242篇 |
2008年 | 370篇 |
2007年 | 386篇 |
2006年 | 335篇 |
2005年 | 323篇 |
2004年 | 284篇 |
2003年 | 270篇 |
2002年 | 234篇 |
2001年 | 68篇 |
2000年 | 68篇 |
1999年 | 53篇 |
1998年 | 25篇 |
1997年 | 21篇 |
1996年 | 20篇 |
1995年 | 13篇 |
1994年 | 11篇 |
1993年 | 16篇 |
1992年 | 33篇 |
1991年 | 23篇 |
1990年 | 28篇 |
1989年 | 32篇 |
1988年 | 23篇 |
1987年 | 25篇 |
1986年 | 25篇 |
1985年 | 18篇 |
1984年 | 24篇 |
1983年 | 18篇 |
1982年 | 17篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 16篇 |
1978年 | 19篇 |
1977年 | 9篇 |
1973年 | 10篇 |
1972年 | 14篇 |
1970年 | 8篇 |
排序方式: 共有6414条查询结果,搜索用时 15 毫秒
21.
Suraj Suresh Mohammad Siddiqui Mouhanna Abu Ghanimeh Jessica Jou Stephen Simmer Vivek Mendiratta Sarah Russell Mustafa Al-Shammari Abigail Chatfield Eva Alsheik Duyen Dang Jeffrey Genaw Tobias Zuchelli 《Obesity research & clinical practice》2021,15(2):172-176
BackgroundAlthough recent studies have shown an association between obesity and adverse coronavirus disease 2019 (COVID-19) patient outcomes, there is a paucity in large studies focusing on hospitalized patients. We aimed to analyze outcomes associated with obesity in a large cohort of hospitalized COVID-19 patients.MethodsWe performed a retrospective study at a tertiary care health system of adult patients with COVID-19 who were admitted between March 1 and April 30, 2020. Patients were stratified by body mass index (BMI) into obese (BMI ≥ 30 kg/m 2) and non-obese (BMI < 30 kg/m 2) cohorts. Primary outcomes were mortality, intensive care unit (ICU) admission, intubation, and 30-day readmission.ResultsA total of 1983 patients were included of whom 1031 (51.9%) had obesity and 952 (48.9%) did not have obesity. Patients with obesity were younger (P < 0.001), more likely to be female (P < 0.001) and African American (P < 0.001) compared to patients without obesity. Multivariable logistic models adjusting for differences in age, sex, race, medical comorbidities, and treatment modalities revealed no difference in 60-day mortality and 30-day readmission between obese and non-obese groups. In these models, patients with obesity had increased odds of ICU admission (adjusted OR, 1.37; 95% CI, 1.07?1.76; P = 0.012) and intubation (adjusted OR, 1.37; 95% CI, 1.04?1.80; P = 0.026).ConclusionsObesity in patients with COVID-19 is independently associated with increased risk for ICU admission and intubation. Recognizing that obesity impacts morbidity in this manner is crucial for appropriate management of COVID-19 patients. 相似文献
22.
Amyn A. Malik Neel R. Gandhi Timothy L. Lash Lisa M. Cranmer Saad B. Omer Junaid F. Ahmed Sara Siddiqui Farhana Amanullah Aamir J. Khan Salmaan Keshavjee Hamidah Hussain Mercedes C. Becerra 《Emerging infectious diseases》2021,27(3):805
In Karachi, Pakistan, a South Asian megacity with a high prevalence of tuberculosis (TB) and low HIV prevalence, we assessed the effectiveness of fluoroquinolone-based preventive therapy for drug-resistant (DR) TB exposure. During February 2016–March 2017, high-risk household contacts of DR TB patients began a 6-month course of preventive therapy with a fluoroquinolone-based, 2-drug regimen. We assessed effectiveness in this cohort by comparing the rate and risk for TB disease over 2 years to the rates and risks reported in the literature. Of 172 participants, TB occurred in 2 persons over 336 person-years of observation. TB disease incidence rate observed in the cohort was 6.0/1,000 person-years. The incidence rate ratio ranged from 0.29 (95% CI 0.04–1.3) to 0.50 (95% CI 0.06–2.8), with a pooled estimate of 0.35 (95% CI 0.14–0.87). Overall, fluoroquinolone-based preventive therapy for DR TB exposure reduced risk for TB disease by 65%. 相似文献
23.
24.
25.
26.
27.
28.
David M. Vail Adnan A. Elfarra A. James Cooley David L. Panciera E. Gregory MacEwen Steve A. Soergel 《Cancer chemotherapy and pharmacology》1993,32(1):25-30
Dexniguldipine-HCl (DNIG) — a prospective clinical modulator of p170-glycoprotein (pgp170)-mediated multidrug resistance (MRD) — was evaluated in a drug-accumulation assay in MDR murine leukemia cell strain F4-6RADR expressing pgp170. The compound elevated low accumulation of either doxorubicin (DOX), daunorubicin (DNR), or mitoxantrone (MITO) in resistant F4-6RADR cells to the very levels observed in drug-sensitive F4-6 precursor cells. In parallel with the increase in DNR content (F4-6RADR, solvent: 303±27 pmol/mg protein; DNIG (3.3 mol/l): 1,067±174 pmol/mg protein; F4-6P, solvent: 948±110 pmol/mg protein;n=8–9, SEM), the amount of DNR tightly bound to the acid precipitate pellet obtained from F4-6RADR (i.e., protein, DNA, RNA) increased 3.9-times to the levels observed in sensitive F4-6 cells. The main pyridine metabolite of DNIG displayed similar activity. Concentration-response analysis revealed that DNIG and R,S-verapamil (VER) induced 100% reversal of the DNR accumulation shortage associated with the MDR phenotype but DNIG was 8 times more potent than VER (50% inhibitory concentration (IC50), 0.73 vs 5.4 mol/l). In keeping with the accumulation assay, DNIG was about 10 times more potent than VER in sensitizing F4-6RADR cells to the cytostatic and cytotoxic effects of DNR in proliferation assays. In conclusion, DNIG is a potent in vitro modulator, improving (a) the accumulation of anthracycline-like cytostatics, (B) drug access to cellular binding sites, and (c) the cytostatic action of DNR in F4-6RADR leukemia cells of the MDR phenotype.Abbreviations DOX
doxorubicin
- CSA
cyclosporin A
- DMSO
dimethylsulfoxide
- DNIG
dexniguldipine-HCl
- DNR
daunorubicin
- MDR
multidrug resistance
- MITO
mitoxantrone
- pgp170
permease glycoprotein 170
- VER
R.S.-verapamil
Dexniguldipine-HCl is the proposed INN for compound B859-35, the R-enantiomer of niguldipine. Segments of this work have been reported in the abstract form 相似文献
29.
Siddiqui N 《Health for the millions》1997,23(4):12-15
India's population has grown since independence from 350 million in 1947 to 950 million in 1997 and will probably reach 1 billion by the year 2000. Projections made from the most recent census indicate that India will be the world's most populous country by 2040. According to World Bank projections, India's population will surpass 1.7 billion by 2097. India's leaders, allocating funds to industrialization, but not enough to health care and education, failed to understand the nature and consequences of high population growth. Rapid population growth in India has led to considerable unemployment among the working-age population, considerable population pressure upon renewable and nonrenewable resources, and a demand for basic facilities which surpasses their supply. The quality of life and the environment have been adversely affected. This paper considers how investments in social development led to the achievement of replacement level fertility in Kerala, Goa, and Tamil Nadu; the sex ratio; child survival; neglect of girls; the politics of population control; and the future. 相似文献
30.